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Patients with castration-resistant prostate cancer (CRPC), who progress after docetaxel therapy, had until very recently, only a few
therapeutic options. Recent advances in this ﬁeld brought about new perspectives in the treatment of this disease. Molecular, basic,
and translational research has given us a better understanding on the mechanisms of CRPC. This great investment has turned
into a more rational approach to the development of new drugs. Some of the new treatments are already available to our patients
outside clinical trials and may include inhibitors of androgen biosynthesis; new chemotherapy agents; bone-targeted therapy; and
immunotherapy. This paper aims to review the mechanisms of prostate cancer resistance, possible therapeutic targets, as well as
new options to treat CRPC.
1.Introduction
Prostate cancer is the most common malignancy in males in
Western countries, representing the second leading cause of
cancer death [1]. Advances in screening and diagnosis have
allowed detection of the disease in early stages (approx-
imately 85% of cases diagnosed), stages at which the ther-
apeutic options are curative and include surgery, radiation
and, in some cases, active surveillance only [2–4]. How-
ever, for late-stage disseminated disease, current therapies
are merely palliative. In 1941, a study of Huggins and
Hodges showed the close relationship of androgens with
prostate tumor growth and androgen-deprivation therapy
(castration) became the key treatment for these stages in
monotherapy or in combination with other methods [2, 4,
5]. Initial responses to castration therapy are quite favorable,
with a signiﬁcant clinical regression and rapid biochemical
responses, as assessed by decline in levels of serum marker,
prostate-speciﬁc antigen (PSA) in 80–90% of patients with
metastatic disease [2, 4, 6]. Despite a good initial response,
r e m i s s i o n sl a s to na v e r a g e2 - 3y e a r s ,w i t he v e n t u a lp r o g r e s -
sion occurring despite castration [4, 5, 7]. In these cases
prostate cancer will progress to a castration-insensitive phase
of disease (Castration-Resistant Prostate Cancer—CRPC)
which carries a worse prognosis and translates into a survival
time of 16–18 months in average from the beginning of
progression [2, 4–6]. Systemic therapies have also been
an option in the management to these patients. However,
chemotherapyisnotwelltoleratedbyallCRPCpatients,who
were often elderly men with limited bone marrow reserve
and concurrent medical conditions [8]. In 2004 the result of
two major phase 3 clinical trials established docetaxel as the
ﬁrst-line chemotherapy regimen in advanced stage disease
[6].
Treatment of patients with CRPC remains a signiﬁcant
clinical challenge. This paper aims to address the mecha-
nisms of resistance in the context of CRPC, as well as new
therapeutic targets, and a brief discussion of current and
future treatments.
2.MechanismsandTargetsinCRPC
The key for the development of new drugs and to optimize
androgenic suppression in advanced stages of CRPC is the
identiﬁcation and characterization of molecular targets and
mechanisms that lead to tumor growth. Disease progression
involves the development of cellular adaptive pathways of2 Prostate Cancer
survival in an androgen-depleted environment [3]. Experi-
mental evidence assigns an important role to the continuous
activation of the androgenic receptors (ARs) in tumor
growth, as well as alternative independent routes [2]. In
general, resistance mechanisms can be divided into 6 groups.
(i) Increased Expression of Enzymes Involved in Steroidoge-
nesis. Studies have suggested that, in CRPC patients, even
castrate serum levels of androgen are still suﬃcient for AR
activation and able to maintain cancer cells survival. Indeed,
the intratumoral levels of testosterone in CRPC patients
are equal of those found in noncastrate patients [4]. The
source of these androgens is thought to be derived from
the synthesis of androgens directly in prostate cancer cells
due to an upregulation of the enzymes and activation of
the routes necessary for the synthesis of androgens such as
testosterone and dihydrotestosterone [3, 5, 9]. Also bone
metastases contain intact enzyme pathways for conversion of
adrenal androgens to testosterone and dihydrotestosterone
[4]. Montgomery and colleagues showed that there was
marked reversal of the DHT:testosterone ratio in the
metastatic tumor. These tumor cells express signiﬁcantly
lower levels of SRD5A2, which catalyses the conversion of
testosterone to DHT, and higher levels of UGT2B15 and
UGT2B17,whichmediatetheirreversibleglucuronidationof
DHT metabolites. Marked up regulation of CYP19A1, which
mediates the aromatization of testosterone to estradiol, was
also observed in the metastases samples [3–5, 9].
(ii) Increased Expression of AR. The overexpression of AR
have been involved in the progression of prostate cancer [3].
The activated AR pathways observed in these CRPC patients
has been postulated as a result of genetic phenomena that
promotesincreasedsensitivityofAR.DNAampliﬁcationsare
responsible for AR overexpression and for its activation in
presence of low levels of ligand (androgens) [3, 9].
(iii) AR Gene Mutations and Altered Ligand Speciﬁcity. While
the androgens are the main factors of tumor growth and AR
signaling,thepresenceofARmutationsleadstoitsactivation
by nonandrogenic steroid molecules and antiandrogens [3].
The majority AR mutations are point mutations in the AR
ligand-binding domain, and initially this was considered
relevant to explain why 10–30% of patients receiving antian-
drogens treatment experience paradoxical PSA drop on
cessation of treatment [5]. However the AR mutations could
occur in other regions such as the amino terminus or the
DNAbindingdomainthatconferoncogenicpropertiestothe
AR [5]. At the present, the role of AR mutations in the anti-
androgen withdrawal phenomena is called into questioned
and a new explanation is oﬀered since the discovery of
alternative splicing of the AR. In fact, in recent reports [6, 7]
it was shown that splice variants of AR with deletion of exons
5, 6, and 7 could result in AR capable to translocate to the
nucleus without ligand binding.
(iv) Downstream Signaling Receptor for Androgens. One of
the most important mechanisms in the development of
castration resistance is the activation of diﬀerent signal
transduction pathways in CRPC cells. They could enhance
theactivityoftheARoritscoactivatorsinthepresenceoflow
levelsorevenintheabsenceofandrogen.Theseincludeother
receptors such as epithelial growth factors, insulin growth
factors, and tyrosine-kinase receptor [7].
(v) Bypass Pathways. The induction of bypass pathways
independent of AR, is an important mechanism of cas-
tration resistance, that can overcame apoptosis induced by
androgen-deprivation therapy. One such example of this is
the up-regulation of antiapoptotic proteins, including the
protein Bcl-2 gene [3, 10].
(vi)StemCells. Prostaticcancerstemcellsarerareandundif-
ferentiated cells that do not express AR on their surface,
being independent of androgens to survive [3]. Currently it
is thought that these cells can be responsible for maintaining
tumorgrowthanddevelopment,becausetheyareabletosur-
vive under androgen-deprivation therapy. The identiﬁcation
of these cells is possible based on the expression of surface
protein (α1β1 integrin and CD133), which could allow new
targets therapies [3].
3. Treatment Options
The growth of prostate cancer is originally androgen depen-
dent and metastatic tumors are generally treated with andro-
gen ablation therapy, with or without antiandrogen sup-
plementation [2, 11, 12]. However, resistance to hormonal
therapy occurs within 12–18 months (remissions last on
average 2-3 years, progression occurs even under castration
[4, 5, 9]), referred to as hormone-refractory or CRPC [2].
Resistance to hormones (in patients with metastatic disease)
is probably shorter than 2-3 years, using PSA. In addition
survival with CRPC is now longer than 16–18 months. Until
recently, patients with castration-resistant prostate cancer
had limited treatment options after docetaxel chemotherapy.
However, in 2010, new options emerged [8]. The three
nonhormonal systemic approaches that have been found to
p r o l o n gs u r v i v a la r ed o c e t a x e la sﬁ r s tl i n e[ 13] chemother-
apy, cabazitaxel as second-line cytotoxic chemotherapy [8,
14],andavaccinenamedsipuleucel-T[15].Anewhormonal
manipulation with abiraterone acetate [14] also showed to
prolong survival in CRPC.
Thecurrentpalliativetreatmentoptionsforpatientswith
CRPC can be divided in diﬀerent groups such as secondary
hormonal therapies, chemotherapy agents, vaccine-based
immune therapy, bisphosphonates, radiotherapy and novel
targets.
3.1. Hormonal Therapies. Drugs that reduce circulating lev-
els of androgens or that competitively inhibit the action
of androgens remain central to the treatment of prostate
cancer. The surgical or medical castration with orchiec-
tomy or gonadotropin-releasing hormone (GnRH) agonists,
respectively, suppresses testicular testosterone generation.
However, the duration of response to castration is shortProstate Cancer 3
(12–33 months) and, in almost all patients, is followed by
the emergence of a castration-resistant phenotype [3]. The
combination with antiandrogens to achieve the maximum
androgen blockade (MAB) did not prove to prolong survival
and 30% of the patients have a drop in PSA after discontin-
uing antiandrogens [3, 16]. Maintenance of oral glucocorti-
coidsatlowerdoses(10mg/day)canresultintemporaryPSA
responses for 25% of the patients, presumably due to adrenal
androgen suppression [3, 17].
For patients whose disease progresses after a MAB, anti-
androgen can be discontinued [18] or can be switched to an
alternative antiandrogen as showed in several reports [18–
20].
High-dose (150mg daily) bicalutamide as second-line
hormonal therapy resulted in ≥50% PSA reduction in 20%–
45% of patients [18, 21–23].
Diethylstilboestrol (DES), a synthetic estrogen, as well as
the other estrogens, suppresses the hypothalamic-pituitary-
gonadal axis and it reduces ≥50% the total PSA in 26% to
66% of patients with CRPC. However, the thromboembolic
toxicity limited is use [18, 24, 25].
Ketoconazol is an antifungal agent that can be given
to CRPC patients after antiandrogen withdrawal because it
inhibitscytochromeP-450enzyme-mediatedsteroidogenesis
in testes and adrenal glands and when given at high-dose
(1200mg/day) or low dose (600mg/day) it resulted in ≥50%
PSA reduction in 27% to 63% and 27 to 46%, of patients,
respectively [18].
Abiraterone acetate, a prodrug of abiraterone, is potent
and highly selective inhibitor of androgen biosynthesis that
blocks cytochrome P450 c17 (CYP 17), a critical enzyme
in testosterone synthesis, thereby blocking androgen syn-
thesis by the adrenal glands and testes and within prostate
tumor [26–30]. The Cou-AA-301 trial compared abiraterone
acetate (1000mg once daily) plus prednisone versus placebo
plus prednisone in patients who had previously received
docetaxel. This study randomly assigned 1195 patients and
the results exceeded the preplanned criteria, with an overall
survival longer in the abiraterone arm (14.8 months versus
10.9 months) (P<0.0001) and with all secondary end
points favoring the treatment group, including time to
PSA progression (10.2 versus 6.6 months) (P<0.001),
progression-free survival (5.6 months versus 3.6 months)
(P<0.001), and PSA response rate (29% versus 6%)
(P<0.001) [26]. The adverse events more frequently related
to abiraterone acetate than to placebo group were urinary
tract infections, adverse events associated with elevated
m i n e r a l o c o r t i c o i dl e v e l ss u c ha sﬂ u i dr e t e n t i o na n de d e m a ,
hypokalemia, and hypertension, as well as cardiac disorders
and liver-function test abnormalities [26].
MDV3100 is an androgen receptor antagonist which pre-
vents nuclear translocation and recruitment of coactivators;
ithasbeenshownantitumoractivityinmenwithCRPCafter
failure of prior hormonal therapy, in phase I/II trial [31, 32].
The AFFIRM trial (a phase III trial) compared MDV3100
versus placebo in patients with docetaxel-refractory CRPC.
[18, 33–35]. A planned interim analysis of the AFFIRM trial
revealed that estimated median survival was 18.4 months for
men treated with MDV3100, compared with 13.6 months
for men treated with placebo (P<0.0001). This translates
into a 37% reduction in the risk for death with MDV3100
(hazardratio,0.631).Asaresult,thetrial’sIndependentData
Monitoring Committee recommended that AFFIRM should
be stopped earlier and that men who were receiving placebo
should be oﬀered MDV3100. The recommendation was
basedonthefactthatthestudy’sprespeciﬁedinterimeﬃcacy
stopping criteria were successfully met. The committee
also examined the safety proﬁle to date and determined
that MDV3100 demonstrated a risk/beneﬁt ratio that was
favorable enough to stop the study.
T h eP R E V A I Lt r i a l( As a f e t ya n de ﬃcacy study of oral
MDV3100 in chemotherapy-na¨ ıve patients with progressive
metastatic prostate cancer) is still ongoing and recruiting
patients.
3.2.Bone-TargetedTherapy:BisphosphonatesandDenosumab.
In men with advanced prostate cancer, the biphosphonate
zoledronate has been shown to prevent or delay skeletal
complications in men with bone metastases, as well as to
palliate bone pain [36, 37]. At an average followup of 24
months, there was a signiﬁcant reduction in the frequency
of skeletal related events (SREs) in men receiving zoledronic
acid compared to placebo (38 versus 49 percent), and the
median time to develop an SRE was signiﬁcantly longer with
zoledronic acid (488 versus 321 days) [38]. Biphosphonates
may also have a role in preventing osteopenia that frequently
accompanies the use of androgen-deprivation therapy [39–
41].
More recent data have show that denosumab is also an
eﬀective treatment for patients with CRPC and bone metas-
tases. In a phase III study denosumab, a human monoclonal
antibody against RANKL, was compared with zoledronic
acid for prevention of skeletal-related events. The results
showed advantage to denosumab, representing another
treatment opportunity for CRPC patients [42].
3.3. External Beam Radiotherapy, Hemibody RT, and Ra-
dioisotope Pharmaceuticals. Focal external beam radiation
therapy (RT) is a palliative treatment possibility that should
be considered for men with CRPC and bone pain that is
limited to one or a few sites. Several clinical trials as well
as a systematic review of the literature suggest that single
treatments with fractionation schedules provide palliation
with cost eﬀectiveness and patient convenience [43–46].
Hemibody RT could also be considered in selected pa-
tients with symptomatic disease limited to one side of the
diaphragm, in order to rapid pain relief, when multiple bone
metastases are present [47].
However, this technique has frequently been replaced by
the administration of radioisotope pharmaceuticals which
may be associated with less toxicity and are more appropri-
ated for patients with multiple painful lesions [48].
In order for these patients to be treated with radioiso-
topes the presence of uptake on bone scan due to metastatic
disease at sites that correlate with pain is necessary. These
radioisotopes are used in men with advanced prostate cancer
with osteoblastic bone metastasis. These patients are often
characterizedbyahighratioofbonetosofttissuemetastases.4 Prostate Cancer
Multiple radioisotopes have been used but the most
extensive data are with 89-strontium (89Sr), Radium-223
and 153-samarium (153Sm). Several clinical trials provide
the rational for the use of this approach in carefully selected
patients [49–55].
Radium-223 is an alpha-emitting pharmaceutical agent
that showed to improve survival in a phase III study [56].
Compared with placebo, Radium-223 was associated with
improved overall survival (median 14.0 versus 11.2 months;
HR, 0.69; P = .002)
3.4. Chemotherapy. Docetaxel is the only approved chemo-
therapy that has been shown to prolong survival among
men with metastatic CRPC. The trial TAX 327 compared
chemotherapy with docetaxel plus prednisone versus mitox-
antrone plus prednisone with a 24% relative reduction for
men with metastatic CRPC and a signiﬁcant survival beneﬁt
(P = 0.009) in the docetaxel arm [11, 30]. Docetaxel was also
eﬀective in pain reduction (35% versus 22%) (P = 0.001)
[11, 30]. In SWOG 9916 trial, docetaxel plus estramustine
was compared with mitoxantrone plus prednisone and
the docetaxel regimen also conferred a signiﬁcant survival
beneﬁt (HR for death 0.80; 95% CI = 0.67–0.97) and
increased median survival (17.5 versus 15.6 months) (P =
0.02) over the mitoxantrone arm [32, 57].
Several docetaxel combinations have been evaluated
in phase 2 studies for CRPC, including associations with
tyrosine kinase inhibitors, antiangiogenesis agents, and
immunologic agents [32, 58]. Phase III trials, combining
docetaxel with other chemotherapy agents, did not demon-
strate superiority to docetaxel plus prednisone [31].
Epothilones, namely, ixabepilone and patupilone, have
shown signiﬁcant activity in men with CRPC [31, 59–62].
These molecules were evaluated in second-line chemother-
apy in two phase II trials after progression with prior taxane
[63, 64]. Phase III trials with ixabepilone are in development
and a phase II trial of patupilone is currently underway [31].
Eribulin mesylate (E7389) is a synthetic analog of the
marine macrolide halichondrin B, which acts as a novel
microtubule modulator with a distinct mechanism of action
(diﬀerentfromtaxanes)[31,63].Anopen-label,multicenter,
single-arm, phase II study was conducted in patients with
CRPC stratiﬁed by prior taxane therapy [31, 65]. Primary
eﬃcacy endpoint was PSA response rate deﬁned as two
consecutive ≥50% decreases in PSA levels from baseline. The
secondary endpoints were duration of PSA response rate and
objective response rate by RECIST criteria. One hundred
and eight patients were available for analyses. Of these 50
were taxane pretreated. Eribulin showed activity in patients
with metastatic CRPR, especially in those with taxane na¨ ıve
disease. Side eﬀects, mainly hematological toxicity (grade 3
and 4 leucopenia and neutropenia), fatigue, and peripheral
neuropathy were manageable [66].
Satraplatin (JM-216) is an oral third-generation plat-
inum compound evaluated in the SPARC trial in combina-
tion with prednisone in second-line therapy after docetaxel
[3, 18]. In this trial, satraplatin plus prednisone resulted
in signiﬁcant improvement in PFS (11.1 weeks versus 9.7
weeks) (P<0.001) but there were no improvement in
median overall survival compared with prednisone alone
(61.3 weeks versus 61.4 weeks) (P = 0.80).
Cabazitaxel, a novel tubulin-binding taxane, is the ﬁrst
chemotherapy shown to improve survival in patients with
docetaxel-refractory metastatic castration resistant prostatic
cancer. In the TROPIC trial, a randomized phase III study
compared cabazitaxel plus prednisone versus mitoxantrone
plus prednisolone, in patients with docetaxel-refractory
prostate cancer. The cabazitaxel arm showed an improve-
ment in median PFS (2.8 months versus 1.4 months) (P<
0.0001), median OS (15.1 months versus 12.7 months),
and lower risk of death (hazard ratio 0.70) (P<0.0001)
[8, 14, 66].
3.5.Vaccines-BasedImmunotherapy. Sipuleucel-T(Provenge,
APC8015) is an autologous dendritic cell vaccine, consisting
of autologous peripheral blood mononuclear cells (PBMCs),
including antigen-presenting cells (APCs), that have been
activatedexvivowitharecombinantfusionprotein(PA2024)
composed of prostatic acid phosphatase (PAP) linked to
granulocyte-macrophage colony-stimulating factor (GM-
CSF) [15]. In the ﬁrst two randomized trials, sipuleucel-
T, the primary endpoint was not accomplished since these
studiesdidnotshowasigniﬁcanteﬀectonthetimetodisease
progressioncomparingwithplacebo.Despitethis,thehazard
ratios were in favor of sipuleucel-T [67, 68]. The subsequent
IMPACT trial, a phase III, randomized trial, in patients with
asymptomatic or minimally symptomatic metastatic CRPC,
designedoverallsurvivalastheprimaryendpoint.Thisstudy
resulted in a 4.1-month improvement in median overall
survival and an improvement in the rate of 3-year survival
(31% versus 23%) in sipuleucel-T arm, with limited toxicity.
However,nosigniﬁcanteﬀectonthetimetoobjectivedisease
progression was observed [15].
GVAX (CGI940/CG8711) is a cellular vaccine composed
of two allogeneic prostate cancer cell lines (LNCaP and
PC-3) that is genetically modiﬁed to secrete GM-CSF [17].
This vaccine showed clinical beneﬁt with limited toxicity
in phase I and II trials [18, 69, 70]. However, the two
phase III trials (VITAL-1 and VITAL-2) evaluated GVAX
against docetaxel plus prednisone in na¨ ıve CRPC and both
were closed prematurely [18, 31]. The VITAL-1 study was
closed when the unplanned futility analysis revealed a <30%
chance of meeting its predeﬁned primary endpoint of OS
improvement and the VITAL-2 terminated when an interim
analysis revealed more deaths in the GVAX arm than in the
control [18, 31, 33, 71].
PROSTVAC-VFisacancervaccineconsistingofarecom-
binant vaccinia vector as a priming immunization with sub-
sequent multiple booster vaccinations, using a recombinant
fowlpox vector. This agent presented in the context of 3 cos-
timulatory molecules (ICAM-1, BLA-7, and LFA-3) which,
when taken together, demonstrate an increase in strength
of the target immunologic response [31]. This vaccine was
evaluated in phase I and II trials. The phase I trial showed
PSA stabilization in 40% of patients and limited toxicity and,
in the phase II study, patients in the PROSTVAC-VF arm
achieved an 8.5-month improvement in median OS (25.1
months versus 16.6 months) and a 44% reduction in theProstate Cancer 5
death rate (Hazard ratio 0.56, P = 0.0061) [72, 73]. Phase III




acid peptides (ET-1, ET-2, and ET-3) that are synthesized
as propeptides and are transformed to their active forms
by sequential endopeptidase and ET-converting enzyme-
mediated cleavage [79]. ETs are regulators of cell prolifera-
tion,vasomotortone,andangiogenesis[31].TheETsbindto
two receptors, endothelin-A (ET-A) and endothelin-B (ET-
B), and play an important role in angiogenesis, proliferation,
escape from apoptosis, invasion, tumor growth, new bone
formation, and bone metastasis [31, 74]. ET and their
receptors have emerged as a potential targets in CRPC
[74, 79]. Eﬃcacy and safety of ET-A receptor blockade—
atrasentan (ABT-627)—have been evaluated in a double-
blind, randomized, placebo-controlled, phase II trial [79].
Two hundred and eighty-eight asymptomatic patients were
randomized to one of three study groups: placebo, 2.5mg
atrasentan, 10mg atrasentan. Primary endpoint was time
to progression. Secondary end points were time to PSA
progression, bone scan changes, and changes in bone and
tumor markers. Target therapy with atrasentan was well
tolerated and results showed a potential to delay progression
of CRPC.
Based on these results other phase III studies also
evaluated atrasentan. In one of these studies [75] atrasentan
did not reduce the risk of disease progression relative to
placebo. However exploratory analyses showed that alkaline
phosphatase and PSA levels were signiﬁcantly lower in the
treatment arm [31]. Another phase III study (SWOG S0421)
tested atrasentan combined with docetaxel/prednisone in
metastatic CRPC as a ﬁrst-line therapy [80]. SWOG trial
S0421 closed earlier based on interim ﬁnding that atrasentan
added to docetaxel and prednisone did not confer additional
survivalbeneﬁttopatientswithhormone-refractoryprostate
cancer.
The Data and Safety Monitoring Committee has deter-
minedthatpatientsinphaseIIIS0421receivingatrasentanin
addition to a standard chemotherapy regimen for advanced
prostate cancer did not have longer survival or longer
progression-free survival. Zibotentan (ZD 4054) is another
ET-A receptor antagonist, which showed evidence of activity
in a randomized phase II trial in men with castrate-
resistantprostatecancerandbonemetastases[81].Following
these results two phase III trials [82, 83]w e r ec o n d u c t e d .
ENTHUSE M0 was discontinued following the results of an
early eﬃcacy review by the Independent Data Monitoring
Committee.Thecompanyhasconcludedthatzibotentanwas
unlikely to meet its primary eﬃcacy endpoints progression
free survival and overall survival. Results from ENTHUSE
M1C are still awaited.
Angiogenesis inhibitors such as thalidomide and beva-
cizumab alone or in combination with docetaxel were
studiedinphaseIItrialswithpromisingresults.Thalidomide
plus docetaxel versus docetaxel monotherapy, in a phase II
trial in patients with metastatic CRPC, showed a ≥50% PSA
decrease (53% versus 37%) (P = 0.32) and improvement in
median overall survival (28.9 months versus 14.7 months)
(P = 0.11) for patients in the thalidomide group [18, 84].
Bevacizumab, a recombinant humanized monoclonal
antibody anti-VEGF, was studied in a phase II, in patients
with docetaxel-refractory CRPC. Bevacizumab plus doc-
etaxel resulted in ≥50% PSA reduction in 55% of patients,
37.5% partial responses, and a median overall survival of
9 months [85]. Bevacizumab, docetaxel and estramustine
resulted in >50% PSA reduction in 75% patients partial
response in 59% of patients and median overall survival of
24 months [86]. However, phase III, CALGB 90401 trial did
notshowimprovementinOS(22.6monthsversus21.5)with
the addition of bevacizumab to docetaxel [18, 76].
The combination of docetaxel, thalidomide, bevacizum-
ab, and prednisolone was also evaluated in a phase II trial
with a ≥50% PSA reduction in 89.6% of patients. The
mediantimetoprogressionwas18.3monthsandthemedian
o v e r a l ls u r v i v a lw a s2 8 . 2m o n t h s[ 87]. More studies are
needed before prescribing angiogenesis inhibitors outside
clinical trials.
Src inhibitors, such as dasatinib, are being studied for
prostate cancer because Src signaling is involved in an-
drogen-induced proliferation. In a phase II trial in chemo-
therapy-na¨ ıve patients with metastatic CRPC, dasatinib
(100mg orally twice daily) showed lack of progression in
43%ofpatientsatweek12andin19%inpatientsatweek24.
Italso revealed adecreasein the markers of bone metabolism
(N-telopeptide and bone alkaline phosphatase) [31]. A
randomized phase III trial with dasatinib plus docetaxel is
ongoing [88].
BlockadeoftheT-cellinhibitoryreceptorCTL-associated
antigen-4 (CTLA-4) augments and prolongs T-cell responses
and is a strategy to elicit antitumor immunity [89]. Ipil-
imumab, an anti-CTLA-4 antibody, was tested in order
to potentiate endogenous antitumor immunity to prostate
cancer through combination immunotherapy with CTLA-
4 blockade and GM-CSF [90]. The results showed that this
combination immunotherapy can induce the expansion not
only of activated eﬀector CD8 T cells in vivo but also of T
cells that are speciﬁc for known tumor-associated antigens
from endogenous immune repertoire.
In a pilot trial of CTLA-4 blockade with ipilimumab
patients with CRPC were given a single dose of 3mg/kg
[89]. Results showed that this approach was safe and did not
result in signiﬁcant clinical autoimmunity. PSA modulating
eﬀe c t sp r e s e n t e dn e e df u r t h e ri n v e s t i g a t i o ni no r d e rt ob e
fully understood.
Two phase III trials are now recruiting patients in order
to compare ipilimumab with placebo [88]. One trial [91]
will evaluate this approach in patients with metastatic
disease, with at least one bone metastasis, prior treatment
with docetaxel, and castrate levels of serum testosterone.
The other trial [77] will include patients with metastatic
castration-resistant prostate cancer who are asymptomatic
or minimally symptomatic and who have not received prior
chemotherapy or immunotherapy.6 Prostate Cancer
Table 1: Summary of the therapeutic impact of new drugs in CRPC treatment.
Reference, study phase, and
patient number Eﬃcacy results PFS∗,O S + Comparator PSA levels/PSA RR#
Docetaxel Tannock et al. [13]
Phase III; 1006 pts
Prolongation of median survival,
decrease in serum PSA level, predeﬁned
reductions in pain and improvements of
quality of life
Mitoxantrone Reduced
Cabazitaxel Bono et al. [65]
Phase III; 755 pts
Improved OS (95% CI: 0.59–0.83,
P<0.0001) and median PFS (HR: 0·74,
0.64–0.86, P<0.0001)
Mitoxantrone Reduced
Abiraterone acetate De Bono et al. [26]
Phase III; 1195 pts
Prolongation of OS, time to PSA
progression (10.2 versus 6.6 months;
P<0.001), progression-free survival (5.6
months versus 3.6 months; P<0.001),




Kucuk et al. [22]
Phase II; 52 pts
Decreases pain and improves symptom
status Baseline after 1st line Reduced (≥50% in
20% pts)








DES Smith et al. [25]
Phase II; 21 pts PSA response rate Baseline after 1st line
hormonal therapy Reduced (43% RR)
Sipuleucel-T Kantoﬀ et al. [15]
Phase III, 512 pts
Relative reduction of 22% in the risk of
death as compared with the placebo
group (hazard ratio, 0.78; 95%
conﬁdence interval (CI), 0.61 to 0.98;
P = 0.03)
Placebo Reduced (≥50% in
2.6%)
MDV3100





Patupilone Beardsley et al. [63]P h a s e
II, 83 pts
Prolongation of PFS, PSA declines, and
pain response (decline) Docetaxel Reduced (≥50% in
46%)
Eribulin Bono et al. [65]





PROSTVAC-VF Kantoﬀ et al. [72]
Phase II; 125 pts
44% reduction in the death rate and an







Carducci et al. [75]
Phase III; 809 pts
Alkaline phosphatase and PSA levels were





Kelly et al. [76]
Phase III; 1050 pts
Improvement in PFS, measurable disease







Sunitinib Sonpavde et al.
[78] Phase II; 36 pts PFS, PSA decline, pain control NA Reduced (≥50% in
12,1%)
∗PFS: progression free survival; +OS: overall survival; #RR: response rate; pts: patients; NA: not available.
Tyrosinekinaseinhibitors(TKIs)areimportantnewclass
of target therapy that interfere with speciﬁc cell signaling
pathways and thus allow target speciﬁc therapy for selected
malignancies. Sorafenib and sunitinib have been tested in
prostate cancer in phase I and II trials.
In the ﬁrst stage of a phase II trial with sorafenib [92]2 2
metastatic CRPC were enrolled. Most of the patients (59%)
had received prior therapy with docetaxel or mitoxantrone.
Sorafenibtherapyfailedtoshow>50%PSAreduction[18].A
secondstageofthetrialwasconductedwith24morepatients
[93]. Of the 24 patients, 21 had previous chemotherapy with
docetaxel. All patients had bony metastases, either alone (in
11) or with soft-tissue disease (in 13). One patient had a par-
tialresponse;10patientshadstabledisease(mediandurationProstate Cancer 7
18 weeks, range 15–48). At a median potential followup of
27.2 months, the median progression-free survival was 3.7
months and the median overall survival was 18.0 months.
For the whole trial of 46 patients the median survival was
18.3 months. The authors concluded that sorafenib has
moderate activity as a second-line treatment for metastatic
castration-resistant prostate cancer in this trial population
[21, 94].
Another phase II study [77] included 57 chemotherapy
na¨ ıve CRPC patients. Fifty-ﬁve patients were evaluable. Two
of these patients had >50% PSA reduction and 15 patients
had stable disease. Analysis of the results from a third phase
II trial suggests that sorafenib therapy could aﬀect PSA
production or secretion regardless of its antitumor activity
[21, 95].
A phase I/II trial of sunitinib in combination with
docetaxel and prednisone showed a PSA response in 56% of
patients, a median time to PSA progression of 42.1 weeks,
and a partial response of measurable disease in 39% patients
[96].
Sunitinib was also tested in CRPC na¨ ıve and docetaxel
refractorypatientsinotherphaseIItrials[94,95].AphaseIII
trial comparing sunitinib plus prednisone versus prednisone
alone, in patients with docetaxel refractorymetastatic CRPC,
is ongoing. Overall survival is the primary endpoint of this
study [18].
Cabozantinib is an inhibitor of MET and VEGFR2 [70].
Both the MET and VEGF-type 2 receptor signaling pathways
appear to play important roles in the function of osteoblasts
and osteoclasts. MET signaling promotes tumor growth,
invasion, and metastasis. Results from cabozantinib trial
were presented at ASCO Meeting, 2011. The authors con-
cluded that cabozantinib showed clinical activity regardless
of prior docetaxel in metastatic CRPC patients, particularly
in patients with bone disease, in addition to improvements
in hemoglobin and tumor regression.
ARQ-197isanoral,selective,nonadenosinetriphosphate
competitive c-MET inhibitor [97]. Results from this clinical
trial showed that ARQ 197 safely inhibited intratumoral
c-MET signaling. Further clinical evaluation focusing on
combination approaches is ongoing. Based on the ﬁrst
reports promising developments are expected.
There are also other potential targets, such as IGF-1R
signaling, vitamin D receptor, PTEN, and phosphoinositide
3-kinase signaling; those are quite promising and could lead
us to new treatment options [3].
Table 1 summarizes the main studies and the therapeutic
impact of new drugs in CRPC treatment.
5. Conclusions
Androgen-deprivation therapy is generally the initial treat-
ment for men with advanced prostate cancer. Diﬀerent
approaches include orchiectomy, LHRH agonist, or a combi-
nation of an LHRH agonist plus an antiandrogen (complete
androgen blockade). Although patients have high response
rates to the initial hormone therapy, nearly all of them
eventually develop progressive, metastatic castrate-resistant,
disease. In these patients other approaches are needed.
We know now that many of these CRPC tumors remain
androgen dependent or AR stimulation dependent. There-
fore it is possible that these patients beneﬁt from sequential
hormonotherapy (e.g., abiraterone acetate) as well as other
new chemotherapy agents or biological approaches.
Individual target therapy is not yet available at this time,
but remains a goal.
Current knowledge about the resistance mechanisms in
castration-resistant prostate cancer has lead to new exper-
iments and has identiﬁed possible new therapeutic targets.
Promising results have already been presented in a broader
spectrum of options. However, the survival beneﬁt of these
drugs in CRPC is still modest and some of the previous
therapeutic options are not yet safe outside clinical trials.
Therefore, well design and with potential clinical impact
phase III trials are warranted, to coroborate the preliminary
results and to answer unmet needs in CRPC.
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